[Other] The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan

buitrungkien Post time 2026-4-14 22:54:12 | Show all posts |Read mode
This post will be closed automatically in 2026-04-17 22:52
Reward40points

The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in JapanShimose, S., Saeki, I., Ito, T. et al. The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan. Hepatol Int 19, 846每855 (2025). https://doi.org/10.1007/s12072-025-10781-y

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
sunnydanesh Post time 2026-4-14 22:54:13 | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    20

Return to the list